There is limited research aimed at understanding the effects of multiple sclerosis (MS) in the Latino community. Although a study conducted in South California found the prevalence lower in Latino individuals than in Black or White individuals, clinicians are seeing a rise in MS diagnoses in the Hispanic community.
To better understand how MS affects Latino individuals living with this disease, Daniel Ontaneda, M.D., Ph.D., and his colleagues conducted a retrospective, cross-sectional study utilizing data from individuals in the Multiple Sclerosis Partners Advancing Technology and Health Solutions (MS PATHS) registry. MS PATHS gathers patient data generated from regular office visits to assist in research programs.
Ontaneda, an associate professor of neurology at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, discussed the findings in a poster presentation this April at the 2023 American Academy of Neurology (AAN) Annual Meeting in Boston, Massachusetts. The abstract was also published late last month in the journal Neurology.
The study included 388 Latinxoand 5,726 non-LatinoWhite patients with MS diagnoses. Each participant had undergone a brain MRI within one year of clinical visits. In comparison with White participants, Latino patients were younger (45 years vs.53 years) and had shorter disease duration (17 years vs. 20 years).
Despite these differences, Latino patients showed lower processing speed, slower walking speed, higher T2 lesion volume (an MRI marker of MS disease progression), and lower thalamic, cortical, and deep gray matter volume.
Ontaneda and colleagues concluded that Latinx patients with MS have more physical disability, cognitive dysfunction, loss of deep gray matter, and greater tissue injury than non-Latino White individuals despite being younger and having a shorter disease duration.
This data is based off of a study conducted by a group of researchers led by Niklas Frahm from the German Multiple Sclerosis Registry to compare the characteristics of patients with MS who switched from their first disease-modifying therapies (DMT) with those of patients who continued taking their first DMT.
Read More
Most Real-World Studies Report Positive Outcomes of Rituximab Use in Multiple Sclerosis
May 8th 2024Although several clinical trials have confirmed the safety and efficacy of rituximab in oncology and autoimmune disease, and even as off-label use in MS, real-world evidence is still necessary to help guide clinicians and managed care professionals in their treatment and coverage decision-making.
Read More
Diabetes Weight Loss Drugs Could be Linked to Reduced Risk of MS, Study Finds
April 12th 2024Drug repurposing has recently emerged as an attractive pathway for developing new treatments due to its relatively fast and cost-efficient trajectory. Because obesity and MS share inflammatory properties, researchers used data from the FDA Adverse Event Reporting System to investigate the association between weight loss-inducing drugs and MS
Read More
Specialty Pharmacist Interventions Result in More Than $150,000 in Cost Avoidance For MS Patients
April 4th 2024Darina Georgieva, Pharm.D., and her colleagues from the department of pharmaceutical services at Vanderbilt University Medical Center, conducted a retrospective observational study to learn the costs avoided through specialty pharmacist interventions for patients at the Vanderbilt MS Clinic. The study results were published in the Journal of Managed Care and Specialty Pharmacy earlier this month.
Read More